ERBB2 and neoplasm: Several other mechanisms, most involving alternative receptor tyrosine kinases, have been proposed as mechanisms of acquired resistance to Her2 inhibition in different cell models [35], underscoring the multitude of “bypass” options [36] that are available for the tumor cell to evade therapy.